RESEARCH OVERVIEW – SOLID TUMORS

As published in numerous academic journals, The DigniCap Scalp Cooling System has been shown to be safe and effective in reducing chemotherapy-induced alopecia in cancer patients with solid tumors. 

Of 226 patients with various solid tumors and undergoing different chemotherapies 65% showed no visible hair loss.

As Published
The influence of various parameters on the success of sensor-controlled scalp cooling in preventing chemotherapy-induced alopecia.
Oncology Research and Treatment (Vol. 38. 2015, 489-495)

Schaffrin-Nabe, D, et al.

Summary

  • The analysis of scalp cooling data of 226 patients with various solid tumors and undergoing different chemotherapies revealed that 65% showed no visible hair loss (CTC grades 0–1), which means 2/3 of patients needed no head cover.
  • These findings directly correspond to the results of Rugo et al. study presented at the ASCO Meeting 2015.
  • The type of substance, dose, and combination of the cytostatics used, the patient’s age, menopausal status, and systemic comorbidities with related regular co-medication, as well as hair density significantly influence the success of scalp cooling; a statistical influence was also seen for nicotine abuse. 

Results

  • 226 patients with various solid tumors were treated with different chemotherapy regimens in the (neo)adjuvant or palliative setting simultaneously to scalp cooling.
  • 146 (65%) patients showed a positive effect of scalp cooling with no or only mild alopecia (not visible, chemotherapy-induced alopecia grades 0 and 1) after completing (neo) adjuvant chemotherapy or after a minimum of 3 months of palliative chemotherapy.
  • 28% of the studied 226 patients opted for a wig.
  • The scalp cooling success rate of the 136 patients with breast cancer receiving different (neo) adjuvant chemotherapies was 65% (88 patients).
  • A subgroup of 76 patients treated with epirubicin cyclophosphamide/paclitaxel scalp cooling was successful in 52 (68%) patients.
  • A total of 5 patients developed chemotherapy-induced alopecia grade 2 after epirubicin cyclophosphamide treatment, but experienced complete hair regrowth during subsequent paclitaxel treatment and successfully finished scalp cooling after chemotherapy with chemotherapy-induced alopecia grade 1. 

Conclusion 

Sensor controlled scalp cooling is an effective supportive method to prevent chemotherapy-induced alopecia. It is well tolerated, and in the majority of cases it generates considerable benefit for the patients.

Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.

OPERATIONS
Dignitana
10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 877-350-2150

HEADQUARTERS
Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90